glp 1 in menopause GLP-1 Microdosing for Perimenopause and Menopause: A Hormone-Aware Metabolic Framework GLP-1s and Hormone Therapy: A

Unrealised Expectations Despite progress, several anticipated 2025 milestones did not come to fruition: Regulatory progress stalled: FDAs obesity drug guidance, published in draft form in January 2025, remains unfinalised, whilst EMA has yet to update its 2016 guideline

The most striking protective effects of SGLT2is were a marked reduction in hospitalization for heart failure and a remarkable reduced progression of chronic kidney disease

The model is easy and affordable to replicate, opening the door for global research into smell loss tied to COVID-19, aging, or diseases like Parkinson s.

Berberine is often called 'nature's metformin' but is the comparison fair

The UKs MHRA recently issued guidance reminding patients using the GLP-1 agonist tirzepatide, who are also on oral contraceptives, that a barrier form of contraception should also be used.

Heres how the weight-loss drug obsession could play out for bev/alc brands